Ashley Gallagher, Associate Editor

CMD drugs understands that pharmacists are on the front lines with patients, necessitating strong communication with providers.

Investigators examined the impact of daily oral tenofovir disoproxil fumarate in combination with emtricitabine to see the effect on the microbiota in South African women.

By targeting the viral conical core, these ARTs could disrupt the process of assembly and/or disassembly of the virus and result in its suppression.

Case studies highlight recent developments and trends in pharmacologic treatments for migraine.

At month 6 post-COVID-19 infection, 123 patients received a diagnosis of type 1 diabetes (T1D) and only 72 were diagnosed with T1D at 6 months post-non-COVID-19 respiratory infection.

New treatments for chronic migraine have been increasing, with robust evidence for eptinezumab, erenumab, fremanezumab, galcanezumab, and onabotulinumtoxin A.

Investigators found that lifestyle changes such as a high-quality diet and regular exercise can lower the risk of type 2 diabetes in women with a history of gestational diabetes mellitus.

The drug shows improvement in exercise capacity and key secondary outcomes compared with the placebo when added to background therapy for those with pulmonary arterial hypertension.

Investigators found that 25% of patients with heart failure with reduced ejection fraction received guideline-recommended intravenous fluids compared to 37% who did not have the condition.

Investigators find that individuals with both conditions are more likely to develop severe disease than those in the control group.

Study results show that intravenous immunoglobulin therapy can help combat this type of PRCA in individuals with anemia.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.

IDH inhibitors show encouraging results in patients with myelodysplastic syndrome, but longer follow ups are needed in a larger patient population to confirm the results.

In a study of 2262 individuals, investigators also found that cocoa extract had no effect on cognition.

Investigators combine research discovery with technological development to determine whether the role of genomics in nephrology should remain with subspecialists or be integrated into general nephrology.

Analyses of more than 30,000 adults in the United Kingdom from 9 prospective cohort studies finds a high pre-pandemic BMI was associated with the infection.

Presentation by Chapman University dean highlights patient relations, staffing issues.

The biosimilar matches Prolia in efficacy, immunogenicity, pharmacodynamics, and pharmacokinetics in women who are postmenopausal with osteoporosis.

Janssen’s GUIDE data demonstrate that patients treated with guselkumab less than 2 years after disease onset vs later are more likely to achieve “super-responder” at week 20 through 28.

Pivotal top-line data demonstrate 20vPnC, if approved likely protects against 20 serotypes in 3-dose series and may offer the broadest serotype coverage of any PCV.

Phase 3 TOPAZ-1 trial of AstraZeneca’s durvalumab demonstrates an improved overall survival benefit.

AstraZeneca’s Lynparza in combination or as a monotherapy demonstrates meaningful survival benefit in long-term follow-up.

Receiving benefits from the SNAP program does not alleviate the issue, according to the analysis.

Analysis shows that individuals who are comfortable sharing their identities with providers are more likely to be satisfied with overall care.

USC Analysis: although generics save US health care systems billions, PBMs jack up prices for employers, government, and patients.

DaxibotulinumtoxinA-lanm from Revance Therapeutics Inc is the first peptide-formulated neuromodulator with long-lasting results.

Panelists discuss pharmacist involvement in effective management, including disease burden and quality of life.

Triplet combination demonstrates a reduction in the risk of disease progression or death in individuals with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.

Part A results from the 2-part LILAC study show that the therapy significantly reduced disease activity based on active joint count in individuals compared with the placebo.